Eagle Pharmaceuticals, Inc. · OTC:EGRX
Eagle Pharmaceuticals — Investor Presentation (June 2022)
10 slides from Eagle Pharmaceuticals's investor presentation, Jun 9, 2022
Slide 1: Company Overview
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 1 1 Company Overview June 9, 2022 The information set forth herein is as of the date of the presentation and is based and conditioned on activities and review which remain ongoing, including FDA review and patent litigation, and is therefore su
Slide 2: Forward-Looking Statements
2 © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and other securities laws. Forward - looking statements are statem
Slide 3: Eagle Pharmaceuticals Financial Position, Portfolio & Pipeline
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 3 Eagle Pharmaceuticals Financial Position, Portfolio & Pipeline *As of 3/31/22; Does not take into account cash consideration paid at recent close of Acacia transaction Share Buybacks $236M* Net Working Capital of $138.5M* Cash + Receivables =
Slide 4: Eagle Portfolio Overview
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 4 Eagle Portfolio Overview RYANODEX ® BARHEMSYS ® Vasopressin BYFAVO ® BENDEKA ® PEMFEXY Œ BELRAPZO ® TREAKISYM SymBio Japan ACUTE CARE HOSPITAL ONCOLOGY Landiolol CAL02 Fulvestrant Commercially Available Products Newly Acquired Pipeline Produc
Slide 5: BARHEMSYS And BYFAVO Are Now Part of the Eagle Portfolio
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 5 BARHEMSYS And BYFAVO Are Now Part of the Eagle Portfolio Through the Completed Acacia Pharmaceuticals Transaction 1 Based on the number of doses per patient at a WAC price of $85 per 10mg dose. 2 Based on market research performed by or for E
Slide 6: Eagle Hospital Business Overview
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 6 ▪ BARHEMSYS and BYFAVO combined U.S. peak sales are estimated to be $275M* ▪ Landiolol U.S. peak sales are estimated to be $100M, if approved* ▪ Anticipate combined U.S. peak sales potential of $375M from BARHEMSYS, BYFAVO and landiolol , if
Slide 7: Eagle Oncology Business Overview
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 7 Eagle Oncology Business Overview BENDEKA ® BELRAPZO ® PEMFEXY Œ TREAKISYM Japan PEMFEXY Œ Launched on February 1, 2022, a ready - to - use liquid in a multi - dose vial with a unique J - code. Approved to treat nonsquamous non - small cell lu
Slide 8: Eagle Currently Has Eight Commercialized Assets Across Hospital and Oncology
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 8 Eagle Currently Has Eight Commercialized Assets Across Our Hospital and Oncology Business ACUTE CARE HOSPITAL Commercially Available RYANODEX ® For treatment of malignant hyperthermia, only formulation that allows for rapid response with 1 vi
Slide 9: Eagle Pharmaceuticals Summary
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 9 Eagle Pharmaceuticals Summary 8 Marketed Products 4 Significant Pipeline Assets Minimal Debt Profitable BENDEKA ® PEMFEXY Œ BELRAPZO ® ONCOLOGY TREAKISYM 1 2 3 4 Pipeline: Fulvestrant SM - 88* HOSPITAL RYANODEX ® BARHEMSYS ® Vasopressin BYFAV
Slide 10: Thank You!
© 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 10 © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. Thank You!
Eagle Pharmaceuticals — Investor Presentation (June 2022) on 6ix